RECRUITING

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity and IR are risk factors for PASC, but will also define fundamental biology that sets the stage for the investigation of novel or existing therapies that target the causal pathways identified.

Official Title

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2 Infection and Inflammation in Human Adipose Tissue

Quick Facts

Study Start:2023-06-06
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05833217

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Ages 18 to 80
  2. * BMI ≥ 25 kg/m2
  3. * not currently pregnant
  1. * pregnancy
  2. * prior liposuction
  3. * recent change in weight (\> 2 kg in one month)
  4. * bleeding disorders
  5. * anticoagulant use
  6. * major organ disease
  7. * diabetes
  8. * history of liposuction
  9. * bariatric surgery
  10. * eating disorders
  11. * psychiatric disorders
  12. * pregnancy or lactation
  13. * recent change in weight (over the past 12 weeks),
  14. * use of weight loss medication or oral steroids
  15. * hematocrit \< 33%
  16. * fasting glucose \>= 126 mg/dL
  17. * blood pressure \>160/100 mmHg

Contacts and Locations

Study Contact

Nicole Turk, BS
CONTACT
6508880144
nturk@stanford.edu

Principal Investigator

Tracey McLaughlin, MD
PRINCIPAL_INVESTIGATOR
Stanford School of Medicine

Study Locations (Sites)

Clinical and Translational Research Unit
Palo Alto, California, 94304
United States
Stanford Health
Palo Alto, California, 94305
United States

Collaborators and Investigators

Sponsor: Stanford University

  • Tracey McLaughlin, MD, PRINCIPAL_INVESTIGATOR, Stanford School of Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-06-06
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2023-06-06
Study Completion Date2025-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Long COVID
  • Insulin Resistance
  • Insulin Sensitivity